Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration

Moataz Abdalkader1, Riikka Lampinen1, Katja M. Kanninen1, Tarja M. Malm1 and Jeffrey R. Liddell*2

1 A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland, 2 Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, VIC, Australia

Ferroptosis is a newly described form of regulated cell death, distinct from apoptosis, necroptosis and other forms of cell death. Ferroptosis is induced by disruption of glutathione synthesis or inhibition of glutathione peroxidase 4, exacerbated by iron, and prevented by radical scavengers such as ferrostatin-1, liproxstatin-1, and endogenous vitamin E. Ferroptosis terminates with mitochondrial dysfunction and toxic lipid peroxidation. Although conclusive identification of ferroptosis in vivo is challenging, several salient and very well established features of neurodegenerative diseases are consistent with ferroptosis, including lipid peroxidation, mitochondrial disruption and iron dysregulation. Accordingly, interest in the role of ferroptosis in neurodegeneration is escalating and specific evidence is rapidly emerging. One aspect that has thus far received little attention is the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). This transcription factor regulates hundreds of genes, of which many are either directly or indirectly involved in modulating ferroptosis, including metabolism of glutathione, iron and lipids, and mitochondrial function. This potentially positions Nrf2 as a key deterministic component modulating the onset and outcomes of ferroptotic stress. The minimal direct evidence currently available is consistent with this and indicates that Nrf2 may be critical for protection against ferroptosis. In contrast, abundant evidence demonstrates that enhancing Nrf2 signaling is potently neuroprotective in models of neurodegeneration, although the exact mechanism by which this is achieved is unclear. Further studies are required to determine to extent to which the neuroprotective effects of Nrf2 activation involve the prevention of ferroptosis.

Keywords: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, motor neuron disease, RSL3, erastin, Keap1, system x̂−

FERROPTOSIS; AN IRON-DEPENDENT NON-APOPTOTIC FORM OF REGULATED CELL DEATH

The last few decades have witnessed a surge in the discovery of new forms of regulated cell death that have immense implications for both health and disease (Galluzzi et al., 2018). Ferroptosis is a recently described form of non-apoptotic regulated cell death caused by uncontrolled iron-dependent lipid peroxidation that is distinct in its morphological, biochemical, and genetic profile from other cell death mechanisms (Dixon et al., 2012; Galluzzi et al., 2018). Cells undergoing
Ferroptosis show none of the classical morphological alterations associated with apoptosis, necroptosis, or autophagy (e.g., cell swelling, nuclear disruption, membrane blebbing, etc.), with the only discernable ultrastructural feature being distinctly altered mitochondrial morphology (Dixon et al., 2012; Stockwell et al., 2017).

A discriminating feature of ferroptosis is the potent capacity of lipid peroxide scavengers (such as ferrostatin-1, liproxstatin-1, and vitamin E) to prevent ferroptotic cell death (Dixon et al., 2012; Friedmann Angeli et al., 2014; Yang et al., 2014). This explicit requirement for lipid peroxidation is a core feature of ferroptosis that distinguishes it from other forms of cell death: ferroptosis inhibitors cannot prevent other forms of cell death (Dixon et al., 2012; Friedmann Angeli et al., 2014; Yang et al., 2014), and conversely classic inhibitors of necrosis, apoptosis, and autophagy do not modulate ferroptosis (Dixon et al., 2012), with the exception of the necroptosis inhibitor, necrostatin-1 (RIPK1 inhibitor), which can inhibit ferroptosis in a necroptosis/RIPK1-independent manner (Friedmann Angeli et al., 2014). The central endogenous suppressor of ferroptosis is the selenoenzyme glutathione peroxidase 4 (Gpx4). Gpx4 detoxifies membrane lipid hydroperoxides, preventing unchecked toxic lipid peroxidation. Gpx4 requires the major cellular antioxidant glutathione as a substrate, and hence ferroptosis is also dependent on glutathione levels (Friedmann Angeli et al., 2014). The precise role of iron in ferroptosis is ironically unclear (see below), however, its involvement is unequivocally indicated by the strong inhibition of cell death associated with iron chelation or limiting iron availability (Figure 1).

Ferroptosis appears to require the presence of specific highly oxidizable phosphatidylethanolamine phospholipids containing the polyunsaturated fatty acids (PUFAs) arachidonic acid and adrenic acid. Acyl-CoA synthetase long-chain family member 4 (ACSL4) is important for the synthesis of phospholipids from these PUFAs, while lysophosphatidylcholine acyltransferase 3 (LPCAT3) is important for their insertion into membrane phospholipids (Kagan et al., 2017). Pharmacological or genetic inhibition of either ACSL4 or LPCAT3 suppresses ferroptosis specifically over other forms of cell death (Dixon et al., 2015; Yuan et al., 2016b; Doll et al., 2017; Kagan et al., 2017). Lipoxigenases can catalyze the formation of lipid hydroperoxides from PUFAs, instigating toxic lipid peroxidation (Yang et al., 2016), although this can instigate independently from lipoxigenase activity (Shah et al., 2017).

As mentioned above, the precise role of iron in ferroptosis remains unclear. The ability of the iron chelators including deferoxamine and deferiprone to salvage cells from ferroptotic death in a variety of models underscores the role of iron in triggering ferroptosis (Dixon et al., 2012; Friedmann Angeli et al., 2014; Yang et al., 2014; Do Van et al., 2016). The lipoxigenases involved in generating toxic lipid hydroperoxides require catalytic iron in their active sites (Abeyasinghe et al., 1996), hence the protective effect of iron chelation has been proposed to involve inhibition of lipoxigenase activity by removal of the essential catalytic iron from these enzymes. Alternatively, iron has been demonstrated to potentiate ferroptosis in a free radical-mediated process independent from lipoxygenase activity (Shah et al., 2017).

Ferroptosis can be experimentally induced by direct inhibition of Gpx4 via Ras-selective lethal small molecule 3 (RSL3) or by genetic knockdown or deletion of Gpx4 (Friedmann Angeli et al., 2014; Yang et al., 2014). As Gpx4 requires glutathione as a substrate, ferroptosis is also induced by disruption of glutathione supply via inhibition of glutathione synthesis (e.g., buthionine sulfoximine) or inhibiting the supply of cysteine required for glutathione synthesis via inhibition of the cysteine-glutamate antipporter system x_c^- (via erastin, sulsafalazine, or sorafenib) (Dixon et al., 2012; Friedmann Angeli et al., 2014) (Figure 1).

Mitochondria play key roles in regulated cell death (Galluzzi et al., 2018), and ferroptosis is no exception. Cells undergoing ferroptosis exhibit specific mitochondrial morphology. Early studies using the system x_c^- inhibitor erastin show ferroptosis results in smaller mitochondria with increased mitochondrial membrane density (Yagoda et al., 2007; Dixon et al., 2012). Later studies employing pharmacological or genetic disruption of Gpx4 causes mitochondrial swelling, decreased cristae and outer membrane rupture (Friedmann Angeli et al., 2014; Doll et al., 2017; Maiorino et al., 2017; Ingold et al., 2018). Toxicity induced by inhibition of mitochondrial complex I can be rescued by ferroptosis inhibitors (Basit et al., 2017). Furthermore, lack of ACSL4 prevents the RSL3-mediated rupture of mitochondrial outer membrane (Doll et al., 2017), while knockdown of mitochondrial acyl-CoA synthetase family member 2 (ACSF2; involved in fatty acid metabolism) prevents erastin toxicity, suggesting ACSF2 generates a mitochondrial-specific lipid necessary for ferroptosis (Dixon et al., 2012).

Despite these observations, evidence for mitochondrial lipid peroxidation during ferroptosis is mixed. Ferroptosis induced by erastin does not appear to be accompanied by mitochondrial lipid peroxidation in vitro (Dixon et al., 2012; Do Van et al., 2016) or in vivo (Wang et al., 2016). In contrast, disruption of Gpx4 causes mitochondrial lipid peroxidation in vitro and in kidneys (Friedmann Angeli et al., 2014). This discrepancy suggests that the inducing stimuli may be critical for the subcellular localization of lipid peroxidation.

Although mitochondria are clearly impaired in ferroptosis, evidence suggests that they are not driving the cell death process. Cells deficient in mitochondria remain sensitive to ferroptosis (Gaschler et al., 2018). Furthermore, extramitochondrial lipid peroxidation temporally precedes mitochondrial lipid peroxidation, and mitochondrial damage including rupture of the outer mitochondrial membrane is a late event, closely preceding cell lysis (Friedmann Angeli et al., 2014; Jelinek et al., 2018).

Reports on targeting antioxidants to mitochondria are mixed. Mitochondrial iron is also implicated in ferroptosis. MitoNEET, also known as CISD1, is an iron-containing protein involved in iron...
FIGURE 1 | Ferroptosis and its molecular regulation by Nrf2. Glutathione peroxidase 4 (Gpx4) utilizes the major cellular antioxidant glutathione (GSH) as a substrate to reduce lipid hydroperoxides (LOOH). Oxidized glutathione (GSSG) generated by Gpx4 is reduced back to glutathione by glutathione reductase (GR) in a reaction requiring NADPH, which can be regenerated by glucose-6-phosphate dehydrogenase (G6PD) and phosphogluconate dehydrogenase (PGD) of the pentose-phosphate pathway, and malic enzyme (ME). The tripeptide glutathione is synthesized by the consecutive action of glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS), where the ligation of cysteine (Cys) and glutamate (Glu) by glutamate-cysteine ligase is the rate-limiting step of glutathione synthesis. The cellular import of cystine by the glutamate-cystine antiporter system $x_{c}^{-}$ constitutes an significant route of cysteine supply for glutathione synthesis. Cysteine is also required for other important cellular antioxidants including thioredoxin (Trx) and thioredoxin reductase (TrxR). Ferroptosis occurs when the Gpx4-catalyzed reduction of lipid hydroperoxides is insufficient to prevent the iron-mediated generation of lipid radicals (LO•). This leads to the propagation of lipid peroxidation and culminates in ferroptosis. Ferroptosis can be experimentally induced by inhibiting Gpx4 via the small molecule inhibitor RSL3, or by limiting glutathione supply to Gpx4. The latter is induced by direct [e.g., buthionine sulfoximine (BSO)] or indirect (e.g., by limiting cysteine availability) inhibition of glutathione synthesis. Cysteine supply is disrupted by inhibitors of system $x_{c}^{-}$ including erastin, sulfasalazine, and sorafenib. Ferroptosis can also be inhibited by iron chelators such as deferoxamine and deferiprone, and lipid radical scavengers such as ferrostatin-1, liproxstatin-1, and vitamin E. Factors transcriptionally regulated by Nrf2 are indicated in blue italics, whereas factors promoting ferroptosis are indicated in red. Clearly Nrf2 signaling is likely to have an integral and pervasive impact on the manifestation of ferroptosis.

export from mitochondria (Mittler et al., 2018). Knockdown of mitoNEET exacerbates erastin toxicity and increases mitochondrial content and lipid peroxidation, whereas stabilization of mitoNEET attenuates erastin toxicity and decreases mitochondrial lipid peroxidation (Yuan et al., 2016a). Alternatively, safely sequestering iron within mitochondria via overexpression of mitochondrial ferritin is able to curb erastin-induced cell death, both in vitro and in vivo (Wang et al., 2016).

EVIDENCE FOR FERROPTOSIS IN NEURODEGENERATION

Explicitly identifying ferroptosis in vivo is hampered by the lack of specific biomarkers. Nevertheless, considerable evidence exists that implicates ferroptosis in neurodegeneration. The association between oxidative stress, lipid peroxidation and neurodegeneration has long been appreciated. Notably, elevated levels of lipid peroxidation are reliably detected in brain tissues and body fluids of Alzheimer’s, Parkinson’s, Huntington’s disease, motor neuron disease and multiple sclerosis patients (Adibhatla and Hatcher, 2010; Shichiri, 2014; Sugiyama and Sun, 2014; Wang et al., 2014; Bradley-Whitman and Lovell, 2015). Iron accumulation is a consistent feature of neurodegeneration (Belaidi and Bush, 2016). The level of iron in brains of individuals with mild cognitive impairment and Alzheimer’s disease correlates with disease progression (Smith et al., 2010; Ayton et al., 2017). Elevated iron is a cardinal feature of Parkinson’s disease substantia nigra (Ayton and Lei, 2014), and increased iron is detected in affected brain regions of patients with motor neuron disease, multiple sclerosis, Huntington’s disease and Friedreich ataxia (Kwan et al., 2012; Li and Reichmann, 2016; Sheykhansari et al., 2018). Reducing brain iron via the chelators deferiprone or deferoxamine is efficacious in clinical trials of Parkinson’s (Devos et al., 2014) and Alzheimer’s patients (Crapper McLachlan et al., 1991), respectively, indicating iron is contributing to the disease process. Further indirect evidence, including diminished glutathione and insufficient Nrf2 signaling (see below), is consistent with the presence of ferroptosis in neurodegeneration (Liddell, 2017; Liddell and White, 2017). Moreover, impaired mitochondrial function is
common to many neurodegenerative diseases (Carri et al., 2017; Liddell and White, 2017; Li et al., 2017; Swerdlow, 2017). Morphologically, mitochondria in brains of mice modeling Huntington’s disease exhibit disrupted cristae (Lee et al., 2011), while those in motor neuron disease human postmortem tissue and model mice feature swollen and vacuolated mitochondria (Jaarsma et al., 2000; Cozzolino and Carri, 2012) reminiscent of the mitochondrial changes evident in ferroptosis.

Since its original characterisation in cancer cells, the concept of ferroptosis has instigated growing efforts to explicitly detect and measure its footprint in neurodegeneration (Guiney et al., 2017; Morris et al., 2018). In this regard, more direct evidence for the role of ferroptosis in neurodegeneration has recently been generated. Neuronal cells are sensitive to erastin and RSL3 toxicity in vitro. This toxicity is associated with mitochondrial impairments, and is rescued by ferroptosis inhibitors or a mitochondrially targeted ROS scavenger (Neitemeier et al., 2017; Jelinek et al., 2018). Genetic models demonstrate the substantial reliance of neurons on Gpx4 to prevent toxic lipid peroxidation. Whereas global deletion of Gpx4 is embryonic lethal (Imai et al., 2003), mice with targeted mutation of Gpx4 selenocysteine to cysteine (sensitive to inactivation), or knockout of Gpx4 specifically in neurons are viable but exhibit selective loss of CA3 hippocampal interneurons, resulting in seizures and early death (Seiler et al., 2008; Ingold et al., 2018). Targeting Gpx4 knockout to photoreceptor neurons results in death of these cells within 21 days of birth (Ueta et al., 2012). Post-development, conditional knockout of Gpx4 in adult mice results in loss of CA1 hippocampal neurons and rapid death, indicating neurons are specifically sensitive to Gpx4 deletion (Yoo et al., 2012). Conditional ablation of Gpx4 targeted to neurons results in dramatic degeneration of motor neurons that rapidly progresses to paralysis and death (Chen et al., 2015). Targeting conditional knockout of Gpx4 to forebrain neurons of adult mice causes cognitive impairments and hippocampal degeneration reminiscent of Alzheimer’s disease (Hambright et al., 2017). These models are all accompanied by lipid peroxidation and mitochondrial impairments, consistent with ferroptosis. Conditional Gpx4 knockout can partially rescued by ferroptosis inhibitors, indicating the involvement of ferroptosis (Chen et al., 2015; Hambright et al., 2017).

Ferroptosis inhibitors have also been investigated in explicit models of neurodegeneration. Ferroptosis inhibitors prevent the toxicity of Huntington’s disease-associated mutated Htt in brain slice cultures (Skouta et al., 2014). Ferroptosis inhibitors are also protective in dopaminergic cultured cells, organotypic slice cultures, and in an MPTP mouse model of Parkinson’s disease (Do Van et al., 2016). Furthermore, ferroptosis is implicated in hemorrhagic and ischemic stroke based on the ability of ferroptosis inhibitors to protect against neuronal death in both in vivo and in vitro models (Li et al., 2017; Tuo et al., 2017; Zille et al., 2017). Ischemic stroke is also strongly modulated by brain iron levels (Tuo et al., 2017). Knockout of glutathione synthesis accelerates the disease phenotype in motor neuron disease-model mice, and ultrastructural analysis of spinal cord tissue reveals mitochondrial swelling, rupture and decreased cristae, all consistent with ferroptosis (Vargas et al., 2011).

Ferroptosis also appears to mechanistically overlap with other cell death modalities in neurodegeneration. Consistent with a distinct form of cell death, it was initially reported that ferroptosis induced by erastin does not involve mitochondrial genes implicated in other cell death pathways, nor the release of cytochrome c (Dixon et al., 2012). However, recent studies show that ferroptosis induces the pro-apoptotic translocation of BH3 interacting-domain death agonist (BID) to mitochondria in neuronal cells (Neitemeier et al., 2017; Jelinek et al., 2018). Oxytosis is described as glutamate-induced inhibition of cystine uptake via system \( x_{c}^{-} \) leading to glutathione depletion and subsequent lipoxygenase-dependent toxic lipid peroxidation (Tan et al., 2001). This is clearly very similar to ferroptosis and has led to the recent proposal that perhaps ferroptosis and oxytosis are in fact the same pathway (Lewerenz et al., 2018). Accordingly, oxytosis in neurons causes mitochondrial morphological changes similar to ferroptosis (Lee et al., 2011), and the toxicity of glutamate mirrors that of erastin or RSL3 in neuronal cells, and are all amenable to prevention by ferroptosis inhibitors (Liu et al., 2015; Neitemeier et al., 2017; Jelinek et al., 2018) or necrostatin-1 (Xu et al., 2007). Furthermore, oxytosis/ferroptosis in neurons involves the translocation of apoptosis inducing factor (AIF) from mitochondria to nucleus, prevention of which alleviates cell death (Xu et al., 2016; Neitemeier et al., 2017; Jelinek et al., 2018). To further complicate the mechanisms of cell death, mitochondrial AIF release is the penultimate stage of parthanatos, a poly ADP-ribose polymerase 1 (PARP-1)-mediated form of cell death (Fricker et al., 2018; Galluzzi et al., 2018). Parthanatos can be induced by oxidative stress, and is also implicated in neurodegeneration (Fricker et al., 2018; Galluzzi et al., 2018). Hence both initiating events and late stages are shared by ferroptosis/oxytosis and parthanatos.

Together these studies show that many features facilitating ferroptosis are present in neurodegeneration, and mounting evidence indicates that targeting ferroptosis with specific inhibitors is a valid therapeutic strategy. However, overlapping mechanisms highlight the need for more comprehensive delineation of the cellular mechanisms of cell death, and the potential for new or repurposed treatments. An alternate approach to attenuate ferroptosis is to augment the endogenous anti-ferroptotic mechanisms within cells. To this end, the role of the transcription factor Nrf2 will now be discussed.

**IS Nrf2 AN ANTI-FERROPTOSIS TRANSCRIPTION FACTOR?**

In terms of endogenous cellular mechanisms preventing ferroptosis, the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is exquisitely positioned to modulate the onset and outcomes of ferroptosis. Nrf2 is responsible for regulating hundreds of antioxidant genes (Gao et al., 2014). Under normal conditions, Nrf2 resides in the cytosol bound to its negative regulator Kelch-like ECH-associated protein 1 (Keap1). Keap1 constitutively targets Nrf2 for ubiquitination and proteasomal degradation, thereby maintaining Nrf2 signaling capacity at a low level. However,
TABLE 1 | Ferroptosis-related genes that are transcriptionally regulated by Nrf2.

| Gene symbol | Gene name | Reference |
|-------------|-----------|-----------|
| GCLM | Glutamate-cysteine ligase modifier subunit | Thimmulappa et al., 2002; Kwak et al., 2003; Lee et al., 2005 |
| GCLC | Glutamate-cysteine ligase catalytic subunit | Thimmulappa et al., 2002; Kwak et al., 2003; Lee et al., 2003; Wu et al., 2011 |
| GSS | Glutathione synthetase | Thimmulappa et al., 2002; Wu et al., 2011 |
| SLC7A11 | System x<sub>c</sub> | Sasaki et al., 2002 |
| GPX4 | Glutathione peroxidase 4 | Lee et al., 2003; Salazar et al., 2006; Wu et al., 2011 |
| GSR | Glutathione reductase | Thimmulappa et al., 2002; Kwak et al., 2003; Lee et al., 2003; Wu et al., 2011 |
| TXN1 | Thioredoxin 1 | Kwak et al., 2003; Lee et al., 2003 |
| TXNRF1 | Thioredoxin reductase 1 | Kwak et al., 2003; Lee et al., 2003; Wu et al., 2011 |
| FTH1 | Ferritin heavy chain 1 | Lee et al., 2003; Pietsch et al., 2003; Wu et al., 2011 |
| FTL | Ferritin light chain | Thimmulappa et al., 2002; Lee et al., 2003; Pietsch et al., 2003; Wu et al., 2011 |
| TFRC | Transferrin receptor 1 | Lee et al., 2003 |
| FPN1 (SLC40A1) | Ferroportin | Marro et al., 2010 |
| MT1G | Metallothionein 1G | Sun et al., 2016a |
| HMOX1 | Heme oxygenase 1 | Alam et al., 1999; Lee et al., 2003 |
| BLVRA | Biliverdin reductase A | Agyeman et al., 2012 |
| BLVRB | Biliverdin reductase B | Wu et al., 2011; Agyeman et al., 2012 |
| FECH | Ferrochelatase | Wu et al., 2011; Campbell et al., 2013 |
| ABCB6 | ATP binding cassette subfamily B member 6 | Wu et al., 2011; Campbell et al., 2013 |
| HRRG1 | Heme-response gene 1 | Campbell et al., 2013 |
| NAPDH regeneration | | |
| G6PD | Glucose-6-phosphate dehydrogenase | Thimmulappa et al., 2002; Lee et al., 2003; Wu et al., 2011 |
| PGD | Phosphogluconate dehydrogenase | Thimmulappa et al., 2002; Wu et al., 2011 |
| ME1 | Malic enzyme 1 | Thimmulappa et al., 2002; Kwak et al., 2003; Lee et al., 2003; Wu et al., 2011 |
| Transcription factors | | |
| PPAR | Peroxoxome proliferator-activated receptor gamma | Cho et al., 2010 |
| PPARC1A | Peroxoxome proliferator-activated receptor gamma coactivator 1α | Neymotin et al., 2011 |

states of increased oxidative stress facilitate the dissociation of Nrf2 from Keap1, and promote the nuclear translocation of Nrf2. In the nucleus, Nrf2 interacts with antioxidant response elements (AREs) in the promoter region of target genes resulting in their transcriptional activation (Yamamoto et al., 2018).

Importantly in the context of ferroptosis, almost all genes thus far implicated in ferroptosis are transcriptionally regulated by Nrf2 (Table 1). These include genes for glutathione regulation (synthesis, cysteine supply via system x<sub>c</sub>, glutathione reductase, glutathione peroxidase 4), NADPH regeneration which is critical for Gpx4 activity (glucose 6-phosphate dehydrogenase, phosphogluconate dehydrogenase, malic enzyme), and iron regulation (including iron export and storage, heme synthesis and catabolism) (Sasaki et al., 2002; Lee et al., 2003; Wu et al., 2011; Kerins and Ooi, 2017). In addition, Nrf2 is involved in the regulation of lipids via the ligand-mediated transcription factor peroxisome proliferator-activated receptor gamma (PPARγ). Nrf2 and PPARγ are reciprocally regulated, with activation of either upregulating the other (Cai et al., 2017; Lee, 2017). PPARγ is a major regulator of lipid metabolism (Cai et al., 2017), and can be activated by oxidized lipids relevant to the initiation of ferroptosis (Itoh et al., 2008). Hence Nrf2 indirectly modulates the lipids whose abundance contributes to the sensitivity to ferroptosis (Doll et al., 2017) (Figure 1).

Nrf2 also plays important roles in modulating mitochondrial function. Nrf2 can be physically bound to mitochondria and thus monitor and respond to changes in mitochondrial function (Lo and Hannink, 2008). Nrf2 also regulates mitochondrial dynamics, including biogenesis (Piantadosi et al., 2008; Merry and Ristow, 2016) via interaction with peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) (Dinkova-Kostova and Abramov, 2015; Navarro et al., 2017), and mitophagy via a P62-dependent, PINK1/Parkin-independent mechanism (East et al., 2014). Mitochondria in Nrf2 knockout mice have impaired function, whereas activation of Nrf2 enhances mitochondrial function and resistance to stressors (Greco and Fiskum, 2010; Neymotin et al., 2011; Holmstrom et al., 2016).

Therefore, by virtue of its direct and indirect regulation of many genes central to ferroptosis and its regulation of mitochondrial function, Nrf2 is positioned to be a key player in ferroptosis. Despite this, the role of Nrf2 in ferroptosis has received very little attention thus far, limited mainly to in vitro studies using cancer cells. As expected, Nrf2 activation confers resistance to ferroptosis in cancer cells (Sun et al., 2016b; Chen et al., 2017a,b; Roh et al., 2017). Genetic modulation of Nrf2 expression, including knockdown and overexpression, can fine-tune the sensitivity of glioma cells to the ferroptosis inducers erastin and RSL3 (Fan et al., 2017). This may contribute to the
cancer-promoting and chemoresistance effects of elevated Nrf2 present in many cancers (Fan et al., 2017; Taguchi and Yamamoto, 2017).

Nrf2 activation is sensitive to shifts in cellular redox status, hence it follows that the lipid peroxidation accompanying ferroptosis should activate Nrf2. Indeed, the ferroptosis inducers erastin and sorafenib are sufficient to activate Nrf2 in hepatocellular carcinoma cells (Houessimon et al., 2016; Sun et al., 2016b). Furthermore, the protective action of the mitochondrially targeted antioxidant, MitoQ, involves Nrf2 activation (Hu et al., 2018).

Given the pervasive lipid peroxidation evident in neurodegeneration, it would be expected that Nrf2 would be elevated in neurodegenerative diseases. While there is some evidence for Nrf2 activation in neurodegeneration, it appears to be relatively mild and clearly insufficient to prevent neuronal dysfunction (Liddell, 2017). In some cases, particularly for motor neuron disease, Nrf2 signaling appears to be impaired (Moujalled et al., 2017). This is in contrast to the strong activation of Nrf2 evident when genetic or pharmacological Nrf2 inducers are applied to models of neurodegeneration (Liddell, 2017). These treatments are robustly neuroprotective in animal models of disease. While several drugs targeting Nrf2 are currently under clinical investigation, to date, dimethyl fumarate (Tecfidera) remains the only clinically approved drug for the treatment of a neurodegenerative disease (relapsing-remitting multiple sclerosis) in which Nrf2 activation clearly contributes to its mechanism of action (Havrdova et al., 2017).

The above mentioned studies in cancer cells provide empirical in vitro support for the anti-ferroptotic action of Nrf2. However, direct in vivo evidence for an anti-ferroptotic effect of Nrf2 induction does not yet exist, and it is currently unknown whether and to what extent the demonstrated neuroprotective efficacy of Nrf2 activation in models of neurodegeneration involve attenuation of ferroptosis. Evaluation of ferroptosis in vivo is currently hindered by the lack of specific markers of ferroptosis. Studies examining the effect of Nrf2 activation in explicit in vivo models of ferroptosis (e.g., Gpx4 knockout) would provide some insight.

CONCLUSION AND FUTURE PERSPECTIVES

Ferroptosis is an iron-dependent form of regulated cell death instigated by impaired glutathione metabolism, culminating in mitochondrial failure and toxic lipid peroxidation. Emerging evidence implicates ferroptosis in neurodegeneration, both in the molecular and biochemical signatures of neurodegeneration, and in terms of functional abrogation of neuron death via specific ferroptosis inhibitors. Elucidating how ferroptosis provokes neurodegeneration will expose new therapeutic opportunities to treat these diseases. To this end, targeting the antioxidant transcription factor Nrf2 is an attractive option. Nrf2 signaling is involved in regulating mitochondrial function and impacts almost all identified molecular aspects of ferroptosis. Treatments targeting Nrf2 have been demonstrated to exert anti-ferroptotic effects in the context of cancer cells, and are beneficial in many models of neurodegeneration. The protective mechanism of Nrf2 activation in these models may involve attenuating ferroptosis via upregulation of the endogenous anti-ferroptotic machinery, however, direct evidence for this is currently lacking. The myriad of Nrf2 actions described here suggest that targeting Nrf2 is an exciting therapeutic option to attenuate ferroptosis.

Several questions remain unanswered. The discovery of bona fide biomarkers of ferroptosis will be invaluable to unequivocally probe its involvement in neurodegeneration and facilitate the development of therapeutic treatments targeting ferroptosis. The continued evaluation of ferroptosis inhibitors and comparison to inhibitors of other cell death modalities in further models of neurodegeneration will help elucidate the key pathways involved. Finally, whether Nrf2 activation is directly alleviating ferroptotic stress.

Taken together, the arguments presented in this review elucidate a coherent network that links Nrf2 signaling to mitochondrial function and ferroptotic cell death, and proposes the targeting of Nrf2 as a rational line of therapy for ferroptotic neurodegeneration.

AUTHOR CONTRIBUTIONS

JL conceived the review. MA prepared the first draft. RL, KK, and TM reviewed literature and contributed to writing. JL prepared the final manuscript.

FUNDING

JL was supported by an Australian National Health and Medical Research Council Peter Doherty Fellowship. We gratefully acknowledge funding from the Academy of Finland and the Sigrid Juselius Foundation, Finland.

REFERENCES

Abeyasinghe, R. D., Roberts, P. J., Cooper, C. E., Maclean, K. H., Hider, R. C., and Porter, J. B. (1996). The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J. Biol. Chem. 271, 7965–7972. doi: 10.1074/jbc.271.14.7965

Adibhatla, R. M., and Hatcher, J. F. (2010). Lipidoxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 12, 125–169. doi: 10.1089/ars.2009.2668

Agyeman, A. S., Chaerkady, R., Shaw, P. G., Davidson, N. E., Visvanathan, K., Pandey, A., et al. (2012). Transcriptomic and proteome profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res. Treat. 132, 175–187. doi: 10.1007/s10549-011-1536-9

Alam, J., Stewart, D., Touchard, C., Boinapally, S., Choi, A. M., and Cook, J. L. (1999). Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274, 26071–26078. doi: 10.1074/jbc.274.37.26071
Ayton, S., Fazlollahi, A., Bourgeat, P., Raniga, P., Ng, A., Lim, Y. Y., et al. (2017). Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain 140, 2112–2119. doi: 10.1093/brain/awx137

Ayton, S., and Lei, P. (2014). Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. BioMed Res. Int. 2014:581256. doi: 10.1155/2014/581256

Basit, F., Van Oppen, L. M., Schockel, L., Bossenbroek, H. M., Van Emst-De Vries, S. E., Hermeling, J. C., et al. (2017). Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis. 8:2716. doi: 10.1038/cddis.2017.133

Belaidi, A. A., and Bush, A. I. (2016). Iron neurochemistry in Alzheimer's disease. Curr. Opinion. Pharmacol. 21, 1585–880. doi: 10.1016/j.coph.2016.05.011

Dinkova-Kostova, A. T., and Abramov, A. Y. (2015). The emerging role of Nrf2 in neuronal cell death. Antioxid. Redox Signal. 22, 195–210. doi: 10.1089/ars.2013.5593

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, M. C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1604–1609. doi: 10.1016/j.cell.2012.06.003

Hu, Q., Ren, J., Li, G., Wu, J., Wu, X., Wang, G., et al. (2018). The mitochondrially targeted antioxidant MitoQ protects the intestinal barrier by ameliorating targeted antioxidant MitoQ protects the intestinal barrier by ameliorating acute renal failure in mice. Am. J. Phys. Lung. Cell. Physiol. 21, 1585–1596. doi: 10.1016/j.chembiol.2014.09.019

San, T., Wirth, A. K., Chen, D., Wruck, C. J., Rauh, M., Buchfelder, M., et al. (2017). Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Redox Biol. 2017:120305. doi: 10.1155/2017.120305

Galluzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., et al. (2018). Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 25, 486–541. doi: 10.1038/cdd.2018.10–1174–2

Hambright, W. S., Fonseca, R. S., Chen, L., Ra, R., and Ran, Q. (2017). Ablation of ferroptosis regulator gluthionate peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 12, 8–17. doi: 10.1016/j.redox.2017.01.021

Havrdova, E., Giavani, G., Gold, R., Fox, R. J., Kappos, L., Phillips, J. T., et al. (2017). Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur. J. Neurol. 24, 726–733. doi: 10.1111/ene.13277

Holmstrom, K. M., Kostov, R. V., and Dinkova-Kostova, A. T. (2016). The multifaceted role of Nrf2 in mitochondrial function. Curr. Opin. Toxicol. 1, 80–91. doi: 10.1016/j.tox.2016.10.002

Houssinon, A., Francois, C., Sauzay, C., Louandre, C., Mongeldar, G., Godin, C., et al. (2016). Metallothionein-I is a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Mol. Cancer 15, 38. doi: 10.1186/s12943-016-0526-2

Hu, Q., Ren, J., Li, G., Wu, J., Wu, X., Wang, G., et al. (2018). The mitochondrially targeted antioxidant MitoQ protects the intestinal barrier by ameliorating mitochondrial DNA damage via the Nrf2/ARE signaling pathway. Cell Death Dis. 9:403. doi: 10.1038/s41419-018-0436-x

Imai, H., Hirao, F., Sakamoto, T., Sekine, K., Mizukura, Y., Saito, M., et al. (2003). Early embryonic lethality caused by targeted disruption of the mouse PHGp gene. Biochem. Biophys. Res. Commun. 305, 278–286. doi: 10.1016/s0006-291x(03)00734-4

Ingold, I., Berndt, C. M., Schmitt, D., Doll, S., Poschmann, G., Buday, K., et al. (2018). Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell 172, 409.e241–422.e241. doi: 10.1016/j.cell.2017.11.048

Itoh, T., Fairall, L., Amin, K., Inaba, Y., Saito, A., Balint, B. L., et al. (2008). Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 15, 924–931. doi: 10.1038/nsmb.1474

Jaarsma, D., Haasdijk, E. D., Grashorn, J. A., Hawkins, R., Van Duijn, W., Verspaget, H. W., et al. (2000). Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates amyotrophic lateral sclerosis in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 7, 623–643. doi: 10.1006/nbd.2000.2929

Jelinek, A., Heyder, L., Daude, M., Plessner, M., Krippner, S., Grosse, R., et al. (2018). Mitochondrial rescue prevents gluthionate peroxidase-dependent...
ferroptosis. Free Radic. Biol. Med. 117, 45–57. doi: 10.1016/j.freeradbiomed.2018.01.019

Kagan, V. E., Mao, G., Qu, F., Angeli, J. P., Doll, S., Croix, C. S., et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90. doi: 10.1038/nchembio.2238

Kerins, M. J., and Ooi, A. (2017). The roles of NRF2 in modulating cellular iron homeostasis. Antioxid. Redox Signal. 2018.10.019

Krausz, T., Gaschler, M. M., Lim, C., Sacher, J. R., Stockwell, B. R., and Wipf, P. (2016). A mitochondrial-targeted nitroxide is a potent inhibitor of ferroptosis. ACS Cent. Sci. 2, 653–659. doi: 10.1021/acscentsci.6b00199

Kwak, M. K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M., and Kessler, T. W. (2003). Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278, 8135–8145. doi: 10.1074/jbc.M211898200

Kwan, J. Y., Jeong, S. Y., Van Gelderen, P., Deng, H. X., Quezado, M. M., Danielian, S. J., et al. (2017). Hydroperoxide- and aldehyde-modified proteins in diseases. Antioxid. Redox Signal. 27, 93–105. doi: 10.1089/ars.2016.6698

Merry, T. L., and Ristow, M. (2016). Nuclear factor erythroid-derived 2-like factor Nrf2 and Ferroptosis in Neurodegeneration. J. Biol. Chem. 278, 278, 12029–12038. doi: 10.1074/jbc.M210870200

Mittler, R., Darash-Yahana, M., Sohn, Y. S., Bai, F., Song, L., Cabantchik, I. Z., et al. (2018). NEET proteins: a new link between iron metabolism, ROS and cancer. Antioxid. Redox Signal. 2018.10.019

Morris, G., Berk, M., Carvalho, A. F., Maes, M., Walker, A. J., and Puri, B. K. (2018). Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neurodegenerative diseases. Behav. Brain Res. 341, 154–175. doi: 10.1016/j.bbr.2017.12.036

Moujalled, D., Grubman, A., Acevedo, K., Yang, S. K., Yu, D. M., Moujalled, D. M., et al. (2017). TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnrNPK and affect the Nrf2 antioxidant pathway. Hum. Mol. Genet. 26, 1732–1746. doi: 10.1093/hmg/ddd093

Navarro, E., Gonzalez-Lafuente, L., Perez-Liebana, I., Buendia, L., Lopez-Bermejo, E., Sanchez-Ramos, C., et al. (2017). Heme Oxygenase-1 and PGC-1alpha regulate mitochondrial biogenesis via microglial activation of alpha7 nicotinic acetylcholine receptors using PNU282987. Antioxid. Redox Signal. 27, 12/15-lipoxygenase dependent- and AIF-mediated cell death. J. Neural Transm. 123, 236–246. doi: 10.1016/j.jnrt.2016.03.027

Pelletier, D., and Deshaies, J. R. (2017). Nexus between mitochondrial function, iron, copper and glutathione in Parkinson’s disease. J. Biol. Chem. 291, 35373–35382. doi: 10.1074/jbc.E116.765298

Pietsch, E. C., Chan, J. Y., Torti, F. M., and Torti, S. V. (2003). Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J. Biol. Chem. 278, 2361–2369. doi: 10.1074/jbc.M210664200

Roh, J. L., Kim, E. H., Jung, H., and Shin, D. (2017). Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11, 254–262. doi: 10.1016/j.redox.2016.12.010

Salazar, M., Rojo, A. I., Velasco, D., De Sagarra, R. M., and Cuadrado, A. (2006). Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem. 281, 14841–14851. doi: 10.1074/jbc.M513737200

Sasaki, H., Sato, H., Kuriyama-Matsunura, K., Sato, K., Maebara, K., Wang, H., et al. (2002). Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277, 44765–44771. doi: 10.1074/jbc.M208742000

Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., McKeen, C., et al. (2008). Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237–248. doi: 10.1016/j.cmet.2008.07.005

Shah, R., Shchepinov, M. S., and Pratt, D. A. (2017). Resolving the role of lipoygenases in the initiation and execution of ferroptosis. ACS Cent. Sci. 4, 387–396. doi: 10.1021/acscentsci.7b00589

Shykhir, F., Kozelko, S., Wawrzkiewicz, R., and Przepiorka, K. (2018). Redox metabolism in multiple sclerosis and amyotrophic lateral sclerosis: a review. Cell Death Dis. 9:348. doi: 10.1038/s41419-018-0579-2

Shichiri, M. (2014). The role of mitocntrion peroxidation in neurological disorders. J. Clin. Biochem. Nutr. 54, 151–160. doi: 10.3164/jcn.14-10

Shimada, K., Shimada, N., Ou, M., Sato, T., and Shichiri, M. (2014). The role of lipid peroxidation in mitochondrial biogenesis. J. Biol. Chem. 289, 115–125. doi: 10.1074/jbc.M113737200

Skouta, R., Sato, T., Wang, J., Dunn, D. E., Orman, M., Shimada, K., et al. (2014). Ferroptostins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551–4556. doi: 10.1021/ja411006a

Smith, M. A., Zhu, X., Tabaton, M., Liu, G., Mckeel, D. W. Jr., et al. (2016). Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19, 363–372. doi: 10.3233/JAD-2010-1239

Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., et al. (2017). Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285. doi: 10.1016/j.cell.2017.09.021

Sugiyama, A., and Sun, J. (2014). Immunochemical detection of lipid hydroperoxide- and aldehyde-modified proteins in diseases. Subcell. Biochem. 77, 115–125. doi: 10.1007/978-94-007-7920-4_10
Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., et al. (2016a). Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. *Hepatology* 64, 488–500. doi: 10.1002/hep.28574
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., et al. (2016b). Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. *Hepatology* 63, 173–184. doi: 10.1002/hep.28251
Swerdlow, R. H. (2017). Mitochondria and mitochondrial cascades in Alzheimer’s disease. *J. Alzheimers Dis.* 62, 1403–1416. doi: 10.3233/JAD-170585
Taguchi, K., and Yamamoto, M. (2017). The KEAP1-NRF2 system in cancer. *Front. Oncol.* 7:85. doi: 10.3389/fonc.2017.00085
Tan, S., Schubert, D., and Maher, P. (2001). Oxytosis: a novel form of programmed cell death. *Curr. Top. Med. Chem.* 1, 497–506. doi: 10.2174/1568026013394741
Thimmulappa, R. K., Mai, K. H., Srismua, S., Kensler, T. W., Yamamoto, M., and Biswal, S. (2002). Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res.* 62, 5196–5203.
Tuo, Q. Z., Lei, P., Jackman, K. A., Li, X. L., Xiong, H., Li, X. L., et al. (2017). Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. *Mol. Psychiatry* 22, 1520–1530. doi: 10.1038/mp.2017.171
Ueta, T., Inoue, T., Furukawa, T., Tamaki, Y., Nakagawa, Y., Imai, H., et al. (2012). Glutathione peroxidase 4 is required for maturation of photoreceptor cells. *J. Biol. Chem.* 287, 7673–7682. doi: 10.1074/jbc.M111.335174
Vargas, M. R., Johnson, D. A., and Johnson, J. A. (2011). Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mouse model. *Neurobiol. Dis.* 43, 543–551. doi: 10.1016/j.nbd.2011.04.025
Wang, P., Xie, K., and Bi, J. (2014). Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. *Eur. Neurol.* 72, 249–254. doi: 10.1159/000363515
Wang, Y. Q., Chang, S. Y., Wu, Q., Gou, Y. J., Jia, L., Cui, Y. M., et al. (2016). The protective role of mitochondrial ferritin on erastin-induced ferroptosis. *Front. Aging Neurosci.* 8:308. doi: 10.3389/fnagi.2016.00308
Wu, K. C., Cui, J. Y., and Klaassen, C. D. (2011). Beneficial role of Nrf2 in regulating NADPH generation and consumption. *Toxicol. Sci.* 123, 590–600. doi: 10.1093/toxsci/kfr183
Xu, X., Chua, C. C., Kong, J., Kostrzewa, R. M., Kumarakurugu, U., Hamdya, R. C., et al. (2007). Nectrin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells. *J. Neurochem.* 103, 2004–2014. doi: 10.1111/j.1471-4159.2007.04884.x
Xu, X., Chua, C. C., Zhang, M., Geng, D., Liu, C. F., Hamdya, R. C., et al. (2010). The role of PARP activation in glutamate-induced necroptosis in HT-22 cells. *Brain Res.* 1343, 206–212. doi: 10.1016/j.brainres.2010.04.080
Yagoda, N., Von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., et al. (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature* 447, 864–868. doi: 10.1038/nature05859
Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018). The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. *Physiol. Rev.* 98, 1169–1203. doi: 10.1152/physrev.00023.2017
Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., and Stockwell, B. R. (2016). Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proc. Natl. Acad. Sci. U.S.A.* 113, E4966–E4975. doi: 10.1073/pnas.1603244113
Yang, W. S., Sriramaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. *Cell* 156, 317–331. doi: 10.1016/j.cell.2013.12.010
Yoo, S. E., Chen, L., Na, R., Liu, Y., Rios, C., Van Remmen, H., et al. (2012). Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. *Free Radic. Biol. Med.* 52, 1820–1827. doi: 10.1016/j.freeradbiomed.2012.02.043
Yuan, H., Li, X., Zhang, X., Kang, R., and Tang, D. (2016a). CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. *Biochem. Biophys. Res. Commun.* 478, 838–844. doi: 10.1016/j.bbrc.2016.08.034
Yuan, H., Li, X., Zhang, X., Kang, R., and Tang, D. (2016b). Identification of ACSL4 as a biomarker and contributor of ferroptosis. *Biochem. Biophys. Res. Commun.* 478, 1338–1343. doi: 10.1016/j.bbrc.2016.08.124
Zille, M., Karuppagounder, S. S., Chen, Y., Gough, P. J., Bertin, J., Finger, J., et al. (2017). Neuronal death after hemorrhagic stroke in vitro and in vivo shows features of ferroptosis and necroptosis. *Stroke* 48, 1033–1043. doi: 10.1161/STROKEAHA.116.015609

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

© 2018 Abdalkader, Lampinen, Kanninen, Malm and Liddell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
